It certainly wouldn't be inappropriate for executives at Toyota's world headquarters in Japan to affix a plaque with this statement at the main corporate entrance: The best of times, the worst of times.
Nursing homes: the role of the long-term care ombudsman
Who truly advocates for nursing home residents in New Jersey and across the United States when they face issues of nursing home negligence or abuse?
Study: "Human factor" core catalyst driving medication errors
"Studies like this give us the opportunity to find out how we are actually doing," says Asad Latif, "compared to how we think we are doing."
Opinion on reusing medical equipment: "Clean and green" initiatives
As one doctor -- an infectious-disease specialist in New York City -- queried recently in his capacity as a media commentator on national health care, what reasonable person would ever argue over a uniform approach to injections that centrally incorporates the notion "one needle, one syringe, only one time"?
FDA's recent order, communication on hip implants: Part II
Please see our immediately preceding products liability blog post of this past Tuesday for relevant background information regarding the FDA's recent issuance of a proposed order aimed at manufacturers of metal-on-metal (MOM) hip implants. The instant post serves as a tandem communication on that subject and provides readers with additional information on the order and the history leading up to it.
FDA issues proposed order on metal-on-metal hip implants
The following information concerning hip implants will be supplemented later this week in a follow-up products liability post that allows for necessary amplification of the subject matter.
Wrongful death litigation continues in Newark-Buffalo plane crash
Many readers undoubtedly remember all too well the fatal air crash of Colgan Air Flight 3407 in early February 2009, a flight departing from New Jersey and destined for Buffalo, New York.
Labeling error: Second recall of thyroid-hormone therapy drug
New Jersey and other users nationwide of the pharmaceutical drug Synthroid might want to pay close attention to drug company AbbVie Inc.'s recent voluntary recall of the thyroid-hormone replacement therapy.
Yale research team questions breast cancer screening costs
If you spend more money on diagnostic screenings for breast cancer, that should logically equate to more accurate diagnoses and, ultimately, less money expended on treatment.
The effects of Sandy on many displaced nursing home residents
Hurricane Sandy was obviously unprecedented, with its effects widespread and far-reaching for literally millions of people in New Jersey, New York and other eastern states.
Breast cancer misdiagnosis, mammograms and Hispanic women
Too much or too little?
N.J. couple's Zoloft complaint added to multidistrict litigation
The anti-depressant drug Zoloft has been a prime cash generator for the pharmaceutical giant Pfizer since it first received approval from the FDA for use in the United States in 1991.
